X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
4.020
+0.030 (0.75%)
At close: Jun 26, 2026, 4:00 PM EDT
4.040
+0.020 (0.50%)
After-hours: Jun 26, 2026, 6:46 PM EDT
X4 Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for X4 Pharmaceuticals stock have an average target of 12, which predicts an increase of 198.51% from the current stock price of 4.02.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for X4 Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $12 | Buy | Initiates | $12 | +198.51% | Jun 2, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $12 | Buy | Maintains | $12 | +198.51% | May 7, 2026 |
Financial Forecast
Revenue This Year
9.50M
from 35.11M
Decreased by -72.94%
Revenue Next Year
9.58M
from 9.50M
Increased by 0.79%
EPS This Year
-0.76
from -1.87
EPS Next Year
-0.91
from -0.76
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 10.8M | 11.0M | |
| Avg | 9.5M | 9.6M | |
| Low | 7.2M | 6.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -69.2% | 15.8% | |
| Avg | -72.9% | 0.8% | |
| Low | -79.5% | -31.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.67 | -0.84 | |
| Avg | -0.76 | -0.91 | |
| Low | -0.96 | -1.05 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.